Jin Hee Noh, Jun Young Shin, Jeong Hoon Lee, Young Soo Park, In-Seob Lee, Ga Hee Kim, Hee Kyong Na, Ji Yong Ahn, Kee Wook Jung, Do Hoon Kim, Kee Don Choi, Ho June Song, Gin Hyug Lee, and Hwoon-Yong Jung. Gut and Liver 2023;17:69-77. https://doi.org/10.5009/gnl210593

Jin Hee Noh, Ji Yong Ahn, Jene Choi, Young Soo Park, Hee Kyong Na, Jeong Hoon Lee, Kee Wook Jung, Do Hoon Kim, Kee Don Choi, Ho June Song, Gin Hyug Lee, Hwoon-Yong Jung, and Jung Mogg Kim. Gut and Liver 2023;17:375-81. https://doi.org/10.5009/gnl220076

Jin Hee Noh, Kee Wook Jung,* In Ja Yoon, Hee Kyong Na, Ji Yong Ahn, Jeong Hoon Lee, Do Hoon Kim, Kee Don Choi, Ho June Song, Gin Hyug Lee, and Hwoon-Yong Jung. J Neurogastroenterol Motil 2023;29:326-34. https://doi.org/10.5056/jnm22121

Noh JH, et al. World J Mens Health. 2025 Jan;43:e3. https://doi.org/10.5534/wjmh.240192

Pih GY, et al. J Korean Med Sci. 2022 Jul;37(29):e227. https://doi.org/10.3346/jkms.2022.37.e227

Background/Aims: The treatment of superficial esophageal neoplasms (SENs) in cirrhotic patients is challenging and rarely investigated. We evaluated the outcomes of endoscopic submucosal dissection (ESD) to determine the efficacy and safety of treating SENs in patients with liver cirrhosis.Methods: The baseline characteristics and treatment outcomes of patients who underwent ESD for SENs between November 2005 and December 2017 were retrospectively reviewed.Results: ESD was performed in 437 patients with 481 SENs, including 15 cirrhotic patients with 17 SENs. En bloc resection (88.2% vs. 97.0%) and curative resection (64.7% vs. 78.9%) rates were not different between the cirrhosis and non-cirrhosis groups (p=0.105 and p=0.224, respectively). Bleeding was more common in cirrhotic patients (p=0.054), and all cases were successfully controlled endoscopically. The median procedure and hospitalization duration did not differ between the groups. Overall survival was lower in cirrhotic patients (p=0.003), while disease-specific survival did not differ between the groups (p=0.85).Conclusions: ESD could be a safe and effective treatment option for SENs in patients with cirrhosis. Detailed preprocedural assessments are needed, including determination of liver function, esophageal varix status, and remaining life expectancy, to identify patients who will obtain the greatest benefit.